BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 38589421)

  • 21. Nav1.6 promotes the progression of human follicular thyroid carcinoma cells via JAK-STAT signaling pathway.
    Li H; Liu J; Fan N; Wang H; Thomas AM; Yan Q; Li S; Qin H
    Pathol Res Pract; 2022 Aug; 236():153984. PubMed ID: 35753135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Tissue-Specific Expressed Hub Genes and Potential Drugs in Rheumatoid Arthritis Using Bioinformatics Analysis.
    Xing X; Xia Q; Gong B; Shen Z; Zhang Y
    Front Genet; 2022; 13():855557. PubMed ID: 35368701
    [No Abstract]   [Full Text] [Related]  

  • 23. The differences in distant metastatic patterns and their corresponding survival between thyroid cancer subtypes.
    Vuong HG; Le MK; Hassell L; Kondo T; Kakudo K
    Head Neck; 2022 Apr; 44(4):926-932. PubMed ID: 35076146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3D modeling in cancer studies.
    Atat OE; Farzaneh Z; Pourhamzeh M; Taki F; Abi-Habib R; Vosough M; El-Sibai M
    Hum Cell; 2022 Jan; 35(1):23-36. PubMed ID: 34761350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
    Hernández Borrero LJ; El-Deiry WS
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188556. PubMed ID: 33932560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extracellular matrix and its therapeutic potential for cancer treatment.
    Huang J; Zhang L; Wan D; Zhou L; Zheng S; Lin S; Qiao Y
    Signal Transduct Target Ther; 2021 Apr; 6(1):153. PubMed ID: 33888679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity.
    Ptacek J; Hawtin RE; Sun D; Louie B; Evensen E; Mittleman BB; Cesano A; Cavet G; Bingham CO; Cofield SS; Curtis JR; Danila MI; Raman C; Furie RA; Genovese MC; Robinson WH; Levesque MC; Moreland LW; Nigrovic PA; Shadick NA; O'Dell JR; Thiele GM; Clair EWS; Striebich CC; Hale MB; Khalili H; Batliwalla F; Aranow C; Mackay M; Diamond B; Nolan GP; Gregersen PK; Bridges SL
    PLoS One; 2021; 16(1):e0244187. PubMed ID: 33444321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor microenvironment as a therapeutic target in cancer.
    Xiao Y; Yu D
    Pharmacol Ther; 2021 May; 221():107753. PubMed ID: 33259885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Therapies for Advanced Thyroid Cancer.
    Laha D; Nilubol N; Boufraqech M
    Front Endocrinol (Lausanne); 2020; 11():82. PubMed ID: 32528402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic Review of Recurrence Rate after Hemithyroidectomy for Low-Risk Well-Differentiated Thyroid Cancer.
    Chan S; Karamali K; Kolodziejczyk A; Oikonomou G; Watkinson J; Paleri V; Nixon I; Kim D
    Eur Thyroid J; 2020 Feb; 9(2):73-84. PubMed ID: 32257956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toll-Like Receptors Signaling in the Tumor Microenvironment.
    McCall KD; Muccioli M; Benencia F
    Adv Exp Med Biol; 2020; 1223():81-97. PubMed ID: 32030686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyroid cancer: incidence and mortality trends in China, 2005-2015.
    Wang J; Yu F; Shang Y; Ping Z; Liu L
    Endocrine; 2020 Apr; 68(1):163-173. PubMed ID: 32002755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methylation exploration for ARDS: a multi-omics and multi-microarray interrelated analysis.
    Zhang S; Wu Z; Xie J; Yang Y; Wang L; Qiu H
    J Transl Med; 2019 Oct; 17(1):345. PubMed ID: 31623626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
    Saleh R; Toor SM; Khalaf S; Elkord E
    Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
    Omar HA; El-Serafi AT; Hersi F; Arafa EA; Zaher DM; Madkour M; Arab HH; Tolba MF
    FEBS J; 2019 Sep; 286(18):3540-3557. PubMed ID: 31306553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk prediction in children and adults less than 45 years old with papillary thyroid cancer.
    Konstantinidis A; Tracy E; Sosa JA; Roman SA
    Expert Rev Endocrinol Metab; 2017 Sep; 12(5):355-365. PubMed ID: 30058890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Insights in Thyroid Cancer and p53 Family Proteins.
    Manzella L; Stella S; Pennisi MS; Tirrò E; Massimino M; Romano C; Puma A; Tavarelli M; Vigneri P
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Themis2: setting the threshold for B-cell selection.
    Deobagkar-Lele M; Anzilotti C; Cornall RJ
    Cell Mol Immunol; 2017 Aug; 14(8):643-645. PubMed ID: 28626236
    [No Abstract]   [Full Text] [Related]  

  • 40. ZCCHC12, a novel oncogene in papillary thyroid cancer.
    Wang O; Zheng Z; Wang Q; Jin Y; Jin W; Wang Y; Chen E; Zhang X
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1679-1686. PubMed ID: 28424903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.